Insulin glargine - HEC Pharm
Latest Information Update: 26 Aug 2016
At a glance
- Originator HEC Pharm
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 05 Nov 2015 Preclinical trials in Diabetes mellitus in China (Parenteral) prior to November 2015 (HEC Pharm pipeline, November 2015)